This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Cansino Biologics Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Innovations of Chunlin Xin in Adenovirus Production
Introduction
Chunlin Xin is a notable inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in the production of adenoviruses. His innovative work focuses on enhancing the safety and efficiency of adenovirus production, which is crucial for vaccine development and other therapeutic applications.
Latest Patents
Chunlin Xin holds a patent for a cell strain designed to reduce the production of replication competent adenovirus. The patent, titled "Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof," introduces the HEK293.CS cell strain. This cell line is engineered by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 cells. The HEK293.CS cell strain maintains its growth and virus production capabilities while eliminating the production of detectable replication competent adenovirus (RCA). This innovation is particularly beneficial for the mass culture of recombinant human type 5 adenovirus, thereby minimizing the risk of RCA production during the manufacturing of vaccines and antibodies.
Career Highlights
Chunlin Xin is currently associated with CanSino Biologics Inc., a company known for its advancements in vaccine development. His work at CanSino has positioned him as a key player in the biotechnology sector, contributing to the development of safer and more effective viral vectors for therapeutic use.
Collaborations
Chunlin Xin collaborates with esteemed colleagues Lei Duan and Zhongqi Shao, who share his commitment to advancing biotechnological innovations. Their combined expertise fosters a collaborative environment that enhances research outcomes and drives progress in the field.
Conclusion
Chunlin Xin's contributions to adenovirus production exemplify the importance of innovation in biotechnology. His patented cell strain represents a significant advancement in the safe production of viral vectors, which are essential for modern medicine. Through his work, Chunlin Xin continues to impact the field positively, paving the way for future developments in vaccine and therapeutic production.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile